Astrana Health Inc provided guidance for 2024, projecting total revenue between $1.65 billion and $1.85 billion. The company expects net income attributable to ASTH to be between $61.0 million and $73.0 million, with an Adjusted EBITDA between $165.0 million and $185.0 million. The diluted EPS is forecasted to be between $1.28 and $1.52. This guidance reflects the company's confidence in its business model and strategic initiatives.